|Dr. Martin Welschof Ph.D.||Pres & CEO||4.75M||N/A||1961|
|Mr. Stefan Ericsson M.B.A.||Chief Financial Officer||N/A||N/A||1963|
|Ms. Marie Moores M.Sc., R.G.N.||Chief Operating Officer||N/A||N/A||N/A|
|Mr. Kristoffer Rudenholm Hansson||Sr. VP of Technical Operations||N/A||N/A||1974|
|Mr. Björn Frendéus||Chief Scientific Officer||N/A||N/A||1973|
|Ms. Cecilia Hofvander||Sr. Director of Investor Relations||N/A||N/A||1967|
|Dr. Andres McAllister||Chief Medical Officer||N/A||N/A||1956|
|Ms. Ingrid Teige||Head of Preclinical Research||N/A||N/A||N/A|
|Ms. Sylvie Ryckebusch||Chief Bus. Officer||N/A||N/A||N/A|
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
BioInvent International AB (publ)’s ISS governance QualityScore as of 1 November 2022 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 1; Compensation: 8.